Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
July 10, 2022 03:00 ET
|
Freeline Therapeutics
FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON, July 10, 2022 (GLOBE NEWSWIRE) -- Freeline...
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
June 24, 2022 09:32 ET
|
Freeline Therapeutics
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene...
uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
July 02, 2021 09:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Freeline presents new Haemophilia B data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting
July 13, 2020 11:45 ET
|
Freeline Therapeutics
- Updated FLT180a data in the B-AMAZE study in severe Haemophilia B patients demonstrated the potential for sustained normal FIX activity levels - - Additional data were presented in 5 poster...
Freeline announces acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting
June 29, 2020 09:00 ET
|
Freeline Logo
- Updated data will be presented in an oral presentation on the efficacy and safety of AAV gene therapy FL180a in the B-AMAZE study in severe haemophilia B patients - - Additional data will be...
uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
July 06, 2019 07:00 ET
|
uniQure Inc.
~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 WeeksAfter Administration of AMT-061 in Phase IIb Study ~ ~ Clinical Benefit and Tolerability of AMT-060 Maintained in All...
uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
June 21, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 21, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...